Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 70-74

  Messa, E ^a   Cilloni, D ^a   Messa, F ^a   Arruga, F ^a   Roetto, A ^a   Saglio, G ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Deferasirox; Iron chelation; Myelodysplastic syndrome; Primary myelofibrosis

Indexed keywords

DEFERASIROX;

AGED; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; PRIORITY JOURNAL;

AGED; BENZOIC ACIDS; BLOOD TRANSFUSION; FEMALE; HEMOGLOBINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 52649145902     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158631     Document Type: Article

References (19)

1. Aul C, Bowen DT, Yoshida Y: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71-86.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
3. Leitch HA: Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(suppl 3):S7-S9 .
4. Chacko J, Pennel DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB: Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on longterm blood transfusions. Br J Haematol 2007;138:587-593.
5. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C: Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 2008;80:168-176.
6. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
7. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, Marchetti M, Morra E, Rebulla P, Visani G, Tura S: Italian Society of Hematology. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-1306.
8. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J, UK MDS Guidelines Group: Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120:187-200.
9. Gattermann N: Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007;31S3:S10-S15.
10. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-4588.
11. Altes A, Remacha AF, Sarda P, Baiget M, Sureda A, Martino R, Briones J, Brunet S, Canals C, Sierra J: Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007;86:443-447.
12. Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Leger CS: Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy (abstract 249). Blood (ASH Annual Meeting Abstracts) 2006;108:78a.
13. Rose C, Brechignac S, Vassilief D, Beyne-Rauzy O, Stamatoullas A, Larbaa D, Guerci A, Roy L, Dumazert L, Mahe B, Cheze S, Quesnel B, Bordessoule D, Dreyfus F, Fenaux P: Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients (abstract 249). A prospective analysis by the GFM. Blood (ASH Annual Meeting Abstracts) 2007;110:80a.
14. Marsh JH, Hundert M, Schulman P: Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990;76:148-149.
15. Jensen PD, Jensen IM, Ellegaard J: Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992;80:121-124.
16. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J: The effect of iron chelation therapy on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-299.
17. Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L, Levi S, Iolascon A: The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007;110:1353-1358.
18. Smeets ME, Vreugdenhil G, Holdrinet RS: Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996;51:243-244.
19. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007;78:540-542.